Expert Insights on Contemporary Issues in Multiple Myeloma

Expert Insights on Contemporary Issues in Multiple Myeloma

An Interactive Symposium

Not a member of My prIME? Join now for instant access.

Meeting Overview

During this live symposium, experts will provide their insight on treatment strategies for initial therapy for transplant eligible/ineligible patients with multiple myeloma (MM), as well as for patients with relapsed and refractory (RR) disease. The increasing number of efficacious novel therapeutics poses a challenge for clinicians, who need to ascertain the efficacy and safety profiles of these emerging therapies and to adapt them to routine clinical practice. The experts will provide a summary on recent key clinical studies and best practices across the entire disease continuum.

A prIME Oncology satellite symposium to be held at the 23rd Congress of the European Hematology Association.

Date and Location

Thursday, 14 June 2018
19.00 – 21.00

Room: K1
Mässvägen 1
Älvsjö, Sweden



Thursday, 14 June 2018
19.00 – 21.00



Stockholm, Sweden



2.0 European CME Credits

Thursday, 14 June

19.00 Welcome, introduction, and quiz
Jesús San Miguel, MD, PhD
19.10 Initial therapy for transplant-eligible patients with MM
Michele Cavo, MD
19.30 Questions from the audience
19.35 Initial therapy for transplant-ineligible patients with MM
Jesús San Miguel, MD, PhD
19.55 Questions from the audience
20.00 Relapsed MM
Meletios Dimopoulos, MD
20.20 Questions from the audience
20.25 Strategies in tertiary-, quad-, and penta-refractory MM
Sagar Lonial, MD
20.45 Questions from the audience
20.55 Closing remarks
Jesús San Miguel, MD, PhD
21.00 Adjourn


  • Jesús San Miguel, MD, PhDUniversidad de Navarra
    Pamplona, Spain
  • Faculty

  • Michele Cavo, MDUniversity of Bologna
    Bologna, Italy
  • Meletios Dimopoulos, MDUniversity of Athens
    Athens, Greece
  • Sagar Lonial, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States

This educational activity is designed for hematologists, medical oncologists, and other healthcare professionals involved in the management of patients with MM.

After successful completion of this educational activity, participants should be able to:

  • Apply recent data from trials of front-line therapy for transplant-eligible patients with MM into clinical practice
  • Identify optimal strategies for initial therapy of transplant-ineligible patients with MM
  • Incorporate potential adverse events of therapeutic agents into the selection of therapy for RR MM in individual patients
  • Describe novel therapies with demonstrated efficacy in patients who have had 4-6 prior lines of therapy for RR MM

This educational activity is supported by Celgene and Karyopharm Therapeutics.

Continuing Education

Expert Insights on Contemporary Issues in Multiple Myeloma held in Stockholm, Sweden, on 14 June 2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 2.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Good CME

Expert Insights on Contemporary Issues in Multiple Myeloma - prIME Oncology


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.